Innovation | Novartis

Media Release
Dec 10, 2024
Longer-term Novartis Kisqali® NATALEE data show durable reduction in distant recurrence in broad population of patients with early breast cancer
Media Release
Dec 08, 2024
Longer-term data for Novartis Scemblix® reinforce superior efficacy with favorable safety and tolerability profile in adults with newly diagnosed CML
Media Release
Nov 25, 2024
Novartis highlights new 96-week results from Phase III Scemblix® ASC4FIRST trial at ASH and late-breaking analysis from Phase III Kisqali® NATALEE trial at SABCS
Media Release
Oct 29, 2024
Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile
Story
Oct 29, 2024
My Journey to Novartis: Finding my Purpose and Passion
Media Release
Oct 24, 2024
Novartis ribociclib (Kisqali®) recognized as Category 1 preferred breast cancer adjuvant treatment by NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)
Media Release
Sep 18, 2024
New Novartis data in relapsing MS reinforce benefits of Kesimpta® for first-line and switch patients
Media Release
Sep 17, 2024
FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer
Story
Aug 02, 2024
Is Diversity, Equity and Inclusion (DEI) really that important?
Media Release
Jul 29, 2024
Novartis Scemblix® granted FDA Priority Review for the treatment of adults with newly diagnosed CML
Media Release
Jul 18, 2024
Novartis erzielt im zweiten Quartal weiterhin kräftige Umsatzsteigerungen und erhöht die Kerngewinnmarge; Gewinnprognose für das Geschäftsjahr 2024 angehoben
Media Release
Jul 18, 2024
Novartis a poursuivi au T2 la forte croissance de son chiffre d’affaires et l’expansion de sa marge core; hausse des prévisions de son résultat opérationnel core pour 2024